Novara

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie … Recruiting
  2023-506662-31-00 4 2024-02-28 Gastric or gastroesophageal cancer
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical … Recruiting
  2024-518888-35-00 4 2024-01-24 amyotrophic lateral sclerosis patients
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 5 2023-12-14 Early stage Follicular Lymphoma
• A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily … Recruiting
  2022-502950-14-00 6 2023-12-08 Partial Lipodystrophy
• Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy … Recruiting
  2023-509793-38-00 4 2023-11-24 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
• A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting
  2022-502273-42-00 5 2023-11-08 Glaucoma
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w … Recruiting
  2022-501808-96-00 4 2023-05-15 Mantle Cell Lymphoma
• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM … Recruiting
  2024-520119-41-00 4 2023-01-15 Previously untreated patients with diagnosis of HCL
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting
  2023-510346-25-00 5 2022-09-01 Hypereosinophilic Syndrome (HES)
• Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with … Recruiting
  2024-514687-33-00 4 2021-12-21 Previously Untreated Chronic Lymphophatic Leukaemia

Showing 97–120 of 234 trials